Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis-Reference-Cited by-同舟云学术

Treatment patterns and outcomes in patients with myelodysplastic syndromes treated with hypomethylating agents: a SEER-Medicare analysis

Published:2021-01-11 Issue:6 Volume:62 Page:1411-1421
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Stein Eytan M.¹,Bonifacio Gaetano²,Latremouille-Viau Dominick³,Shi Sherry³,Guerin Annie³,Wu Eric Q.⁴,Sadek Islam²,Cao Xiting²

Affiliation:

1. Leukemia Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

2. Health Economics and Outcomes Research, US Oncology, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA

3. Analysis Group, Inc., Montreal, QC, Canada

4. Analysis Group, Inc., Boston, MA, USA

Funder

Novartis Pharmaceuticals Corporation

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

https://www.tandfonline.com/doi/pdf/10.1080/10428194.2020.1869959

Reference50 articles.

1. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes

2. Howlader N, Noone AM, Krapcho M, et al. editors. SEER Cancer Statistics Review, 1975-2017, National Cancer Institute, Bethesda, MD, based on November 2019 SEER data submission, posted to the SEER website, April 2020. Available from: https://seer.cancer.gov/csr/1975_2017/

3. The Epidemiology of Myelodysplastic Syndromes

4. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs

5. Myelodysplastic syndromes

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SOHO State of the Art Updates and Next Questions: An Update on Higher Risk Myelodysplastic Syndromes;Clinical Lymphoma Myeloma and Leukemia;2024-09

2. Oral decitabine–cedazuridine versus intravenous decitabine for myelodysplastic syndromes and chronic myelomonocytic leukaemia (ASCERTAIN): a registrational, randomised, crossover, pharmacokinetics, phase 3 study;The Lancet Haematology;2024-01

3. Clinical Outcomes in Patients With Refractory Anemia With Excess Blasts (RAEB) Who Receive Hypomethylating Agents (HMAs);Clinical Lymphoma Myeloma and Leukemia;2023-10

4. Treatment patterns, resource utilization and clinical outcomes in patients with higher risk myelodysplastic syndromes (MDS) in United States community practices;Leukemia & Lymphoma;2023-09-07

5. Overview of the Management of Higher-Risk Myelodysplastic Syndromes;The Cancer Journal;2023-05